Top of the morning to you. Another deliciously shiny day is unfolding over the Pharmalot campus, where the skies are blue and a cool breeze is circulating. Although there is much work to be done, please join us as we pause ever so briefly to relish the moment with a tasty cup of stimulation. After all, life is short, so why not stop to appreciate, yes? Our choice today is vanilla macadamia nut, for those who track this sort of thing. Once you’ve finished, you can dig in to the menu of interesting items below. And of course, have a wonderful day. …
Teva Pharmaceutical reached a national settlement agreement worth up to $4.25 billion to resolve thousands of lawsuits over its alleged role in the opioid crisis, the Associated Press writes. Under the terms, the generic drugmaker would pay more than $3 billion over the next 13 years to states and local governments, plus another $100 million to Native American tribes. The total sum covers previous lawsuit settlements Teva reached with governments. The company will also supply up to $1.2 billion of its generic version of the opioid overdose-reversal drug Narcan over 10 years. States, local governments, and tribes still need to sign off on the deal.
The U.S. Justice Department has opened a criminal investigation into Cassava Sciences involving whether the company manipulated research results for its experimental Alzheimer’s drug, Reuters reports. The company already was facing scrutiny from the U.S. Securities and Exchange Commission and investors after two doctors from outside Cassava last year alleged data manipulation and misrepresentation involving research underpinning the drug, called simufilam. The criminal investigation began sometime after a petition was filed in August 2021 with the U.S. Food and Drug Administration by a lawyer on behalf of two physicians asking the agency to halt clinical trials of the drug.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect